Regeneron Pharmaceuticals, Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Collaboration Revenue at $7.3 billion, 51% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
16,896
|
14,343
|
14,202
|
13,117
|
12,173
|
16,072
|
8,497
|
6,558
|
5,146
|
5,872
|
4,860
|
| Collaboration Revenue |
9,326
+33.9%
share 55.2%
|
7,331
+21.0%
share 51.1%
|
6,058
+10.1%
share 42.7%
|
5,503
+12.0%
share 42.0%
|
4,914
+33.8%
share 40.4%
|
3,673
share 22.9%
|
—
|
—
|
—
|
—
|
—
|
| Product |
6,657
+0.3%
share 39.4%
|
6,309
-17.3%
share 44.0%
|
7,629
+7.8%
share 53.7%
|
7,078
+2.7%
share 54.0%
|
6,894
-43.1%
share 56.6%
|
12,117
+117.6%
share 75.4%
|
5,568
+15.2%
share 65.5%
|
4,834
+17.7%
share 73.7%
|
4,106
+10.4%
share 79.8%
|
3,718
share 63.3%
|
—
|
| Product And Service Other |
913
+41.9%
share 5.4%
|
703
+36.4%
share 4.9%
|
515
-3.9%
share 3.6%
|
536
+46.8%
share 4.1%
|
365
+29.8%
share 3.0%
|
281
-49.5%
share 1.7%
|
557
+220.1%
share 6.6%
|
174
share 2.7%
|
—
|
—
|
—
|
| Other Products |
41
share 0.2%
|
10
share 0.1%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- REGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NY
- Headquarters
- Tarrytown, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 872589
- Former names
- REGENERON PHARMACEUTICALS INC (until Jun 19, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.